Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valsartan - Novartis

Next Previous
X
Search
Drug Profile

Valsartan - Novartis

Alternative Names: CGP-48933; Diovan; Diovane; Kalpress; Miten; Nisis; Provas; Tareg; Valpression; Vals; Varexan

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer ESTEVE; JW Pharmaceutical; Novartis; Zeneca Farma
  • Class Antihypertensives; Branched-chain amino acids; Cardiovascular therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension; Heart failure; Hypertension; Postmyocardial infarction
  • Discontinued Kidney disorders; Pulmonary fibrosis; Type 2 diabetes mellitus

Most Recent Events

  • 01 Feb 2023 Discontinued - Phase-III for Hypertension (In children) in Belgium, France, Germany, Hungary, Italy, Lithuania, Poland, Spain, Guatemala, Brazil (PO)
  • 06 Jan 2020 No development reported - Phase-III for Hypertension (In children) in Spain, Poland, Lithuania, Italy, Hungary, Germany, France, Belgium, Brazil, Guatemala (PO)
  • 31 Aug 2019 Efficacy and adverse events data from a phase III trial in Hypertension, with or without chronic kidney disease presented at the Annual Congress of the European Society of Cardiology (ESC-2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top